NSCLC Clinical Trials in Changsha, Hunan
18 recruitingChangsha, Hunan, China
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC520 enrolled156 locationsNCT06305754
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC614 enrolled218 locationsNCT06170788
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 3
IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed
iO Resistant sqNSCLC
Fortvita Biologics (USA)Inc.600 enrolled44 locationsNCT07217301
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC556 enrolled194 locationsNCT06074588
Recruiting
Phase 2
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
MTAP-deleted NSCLC
Amgen200 enrolled91 locationsNCT06593522
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 2
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
NSCLCSintilimabAdaptive Radiotherapy
The Third Xiangya Hospital of Central South University35 enrolled1 locationNCT07138755
Recruiting
Phase 2
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Breast CancerNSCLCHNSCC+1 more
MediLink Therapeutics (Suzhou) Co., Ltd.200 enrolled82 locationsNCT06107686
Recruiting
Phase 3
Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
Hunan Province Tumor Hospital156 enrolled2 locationsNCT07251582
Recruiting
Phase 2
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
NSCLC
Tang-Du Hospital27 enrolled3 locationsNCT06864624
Recruiting
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
NSCLC
Hunan Province Tumor Hospital100 enrolled1 locationNCT05991193
Recruiting
Phase 2
PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
HER2 Insertion Mutation Positive Advanced NSCLC
Yongchang Zhang30 enrolled1 locationNCT04144569
Recruiting
Phase 2
A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
NSCLC
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.120 enrolled1 locationNCT06361927
Recruiting
Phase 3
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
NSCLCEGFR Activating Mutation
TYK Medicines, Inc680 enrolled2 locationsNCT05382728
Recruiting
A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC
NSCLC
Hunan Province Tumor Hospital200 enrolled1 locationNCT05991206
Recruiting
Phase 1
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NSCLC
Haisco Pharmaceutical Group Co., Ltd.220 enrolled12 locationsNCT06050980